CCR5 antagonist 2 (Compound 25) 是一种CCR5拮抗剂,其IC50为 8.34 nM。CCR5 antagonist 2 显示广谱抗HIV-1活性。
生物活性 | CCR5 antagonist2 (Compound 25) is aCCR5antagonist with anIC50of 8.34 nM.CCR5 antagonist2 shows broad-spectrum anti-HIV-1activities[1]. |
IC50& Target[1] | CCR5 8.34 nM (IC50) | HIV-1 11 nM (EC50, TZM-bl cell) |
|
体外研究 (In Vitro) | CCR5 antagonist 2 (Compound 25) (48 h) 在 TZM-bl 细胞中表现出优异的 HIV-1 抑制活性,EC50为 0.011 ± 0.002 μM[1]。 CCR5 antagonist 2 (48 h) 对 TZM-bl 细胞中亲 CCR5 整合酶抑制剂耐药株 HIV-1YU-2(G140S/Q148H)具有抗病毒活性,EC50为 4.34 ± 1.61 nM[1]。 CCR5 antagonist 2 对 HIV-1 菌株 KIZ001、YU-2、KIZ006、SF162 和 Ba-L 有抑制作用,EC50分别为 7.82、8.73、12.61、15.99 和 16.93 nM[1]。
|
体内研究 (In Vivo) | PK Properties of CCR5 antagonist 2 (Compound 25) in SD Rats[1]
compd | admin | dose (mg/kg) | Cmax(ng/mL) | Tmax(h) | T1/2(h) | AUC0–last(ng·h/mL) | AUC0–∞(ng·h/mL) | MRT (h) | CL (mL/min/kg) | F (%) | CCR5 antagonist 2 | p.o. | 10 | 49.5 ± 18.6 | 2.0 ± 0.0 | 10.3 ± 2.5 | 229 ± 92 | 283 ± 105 | 13.2 ± 4.2 | – | 15.7 | | i.v. | 2 | – | – | 1.60 ± 0.03 | 291 ± 75 | 298 ± 76 | 1.81 ± 0.04 | 117 ± 29 | |
Animal Model: | SD rats[1] | Dosage: | 2 mg/kg and 10 mg/kg | Administration: | Intravenous and oral administration (Pharmacokinetic Analysis) | Result: | Displayed good PK profiles. |
|
分子量 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |